Senior Manager, Strategy & Portfolio Analytics

This role is considered Hybrid.

Overview

The Senior Manager, Strategy and Portfolio Analytics will report to the Senior Director, Portfolio Analytics and will aid in building and advancing our analytical capabilities for analyzing our pipeline of potential drugs ranging from pre-clinical assets through registration and assisting asset teams with fit-for-purpose analyses of alternative clinical development paths and life cycle management strategies. Familiarity with multiple portfolio and asset analytical frameworks, as well as emerging analytical tools and capabilities, is desired. This role will also support the Enterprise Strategy Team with its strategic projects, examples of which may include refreshing the corporate strategy or disease area strategy development.

The role will require an ability to multi-task and prioritize multiple initiatives. This individual will work cross-functionally as a trusted partner to cross-functional teams. Success will require an aptitude for translating analytics into insights in a way that engages and influences leaders to focus on business needs and key strategic questions. Insights generated in this role will be an important input to Alnylam's strategies at an enterprise, disease area and asset level.

This individual will also support efforts to advance our portfolio analytical capabilities which will include consideration for leveraging enterprise tools, adding appropriate AI capabilities, and building standardized models and tools with the goal of providing data and insights that inform strategic portfolio decisions. Advancing our capabilities will also include identifying critical data needs and available data and analytics resources, as well as monitoring emerging vendor capabilities.

Given the rapid growth and breadth of our portfolio, the ideal candidate must be able to productively work within an uncertain and context shifting environment, work effectively in a matrix organization and with multiple cross-functional teams, and be able to pivot quickly in response to rapidly changing business conditions. The ability to think creatively, minimize process, drive data and analytics to implications, and rapidly move from idea creation to tangible plans will be critical to success.

Key Responsibilities

• Build and advance our portfolio analytic capabilities to successfully integrate our scientific approach, our development, commercial, and financial forecasts, and competitive landscape analyses to generate actionable insights and inform critical strategic decisions at the enterprise, disease area, and asset level
• Assist asset teams by providing industry benchmarks or comparative internal data for critical analysis inputs (e.g., PTRS, study size, cost per patient) and develop fit-for-purpose analytical models and tools to support evaluation of alternative clinical development paths and life cycle management strategies
• Work cross-functionally to improve the quality of data inputs which underpin the portfolio analysis and strategy development efforts
• Support enterprise strategy projects by conducting landscape analyses, aiding in strategy development, developing analytical tools to gain insight from alternative future scenarios, and drafting effective presentations
• Help the team assess new and emerging analytical tools and methodologies, including how best to leverage AI capabilities and incorporate these capabilities into our analytical processes and toolkit
• Refine our analytical processes to improve efficiency, drive focus toward higher-order analyses, and standardize analytical output
• Maintain up-to-date library of portfolio and asset level metrics and cross-asset comparisons and track variance over time, where appropriate
• Demonstrate strong stakeholder management and influencing skills and translate analytics into dialogue to address business issues and inform strategic decisions

Qualifications

• Must have 4+ years' experience in portfolio analytics and/or corporate strategy roles with a biopharma having over 10 clinical assets with different disease prevalences across more than 3 disease areas
• MBA and/or MS Biotechnology or other life science focused discipline
• Strong understanding of drug development, including experience with clinical development paths, regulatory hurdles, and key commercial inputs, including pricing and market access
• Demonstrated ability to conduct analyses, present outputs, and translate analytics into strategic insights that will inform decision-making and/or address business challenges
• Strong aptitude for effectively working with senior leadership and executive team members
• Strong understanding of financial statements
• Strong problem solving, project management, and communication skills
• Excellent interpersonal skills and ability to work effectively across multiple functions
• Self-starter who can manage through ambiguity, learn on the fly, handle multiple priorities and perform job responsibilities accurately while working in a high energy, deadline-driven, and fast-paced environment
• Enthusiastic team member with the ability to quickly gain trust and respect of peers and leadership and a track record of successfully driving results through partnership with others

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.